biopharmaceuticals

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven…

1 week ago

Servier completes the acquisition of Day One Biopharmaceuticals

Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong…

2 weeks ago

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment

KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly…

1 month ago

XTL Biopharmaceuticals Announces ADS Ratio Change

March 20, 2026 16:10 ET  | Source: XTL Biopharmaceuticals Ltd. RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL…

2 months ago

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric…

2 months ago

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:  Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.…

9 months ago

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that…

11 months ago